News items Chemotherapie gericht losklikken leidt tot goede resultaten in muizen
4 May 2018

Tagworks Pharmaceuticals, based at Radboud university medical center, has developed a new technique for the targeted delivery of chemotherapy for tumors in cases where this was previously very difficult. By way of the controlled ‘click-to-release’ of the chemotherapy drug from its tumor-binding carrier, the chemotherapy can be activated at the right location. The company is publishing the results of studies in mice that have been treated with this method in Nature Communications.

Antibody Drug Conjugates (ADCs) are relatively new anti-cancer drugs. They consist of an antibody to which a cell-killing molecule (chemotherapy) is attached. Antibodies can recognize and bind to certain receptors (the ‘hands’ on the outside of a cell) in a very targeted way. The antibody in an ADC is designed to adhere exclusively to receptors that are characteristic of a tumor cell. The chemotherapy drug is not released until the receptor has brought the entire structure into the cell, and then the chemotherapy drug can do its job.
 
ADCs are currently already used for the treatment of lymphoma and metastatic breast cancer. “These ADCs work very well,” says Marc Robillard of Tagworks Pharmaceuticals, a company based at Radboud university medical center. “But for many other tumors, including colon cancer and ovarian cancer, this method is not yet applicable. The problem is that there are not many suitable cancer-specific receptors that automatically drag such an ADC into the cell, and if the ADC gets stuck on the outside, the chemotherapy drug will not be released and therefore can’t do its job.”
 
Chemotherapy drug released
It is vital to ensure that the chemotherapy drug is also released if the ADC remains on the outside of the tumor cells. To achieve this objective, Tagworks has designed a smart variant of the ADCs. The ADC is injected and then binds to the receptors on the tumor cells. After a day or two, the tumor is filled with these ADCs. So far, this is nothing new. Robillard: “Our innovation is that we inject a second component that ‘click-releases’ the chemotherapy drug from the ADC. As a result, a large quantity of chemotherapy is released very quickly, attacking the tumor. This method will hopefully enable us to treat many more types of cancer.”
 
Effective in mice
The first results of this new ‘click-to-release’ method in mice have now been published in Nature Communications. Robillard: “We studied ovarian cancer and an aggressive form of colon cancer. In both cases we observed a pronounced anticancer effect. For control purposes, we also applied a ‘traditional’ ADC, i.e., without the second component that causes the chemotherapy drug to release, but this approach had no therapeutic effect  in these forms of cancer.”
 
Cooperation
In Nijmegen, Tagworks collaborates with a variety of research groups, Technology Centers and Research Facilities, which have been specifically set up for cooperation with the business community, including the Radboudumc Technology Center for Mass Spectrometry. In addition, Tagworks cooperates with specialized small and medium-sized enterprises that are also co-authors of the publication. According to Robillard, this illustrates the importance of cooperation. “Developing new drugs for cancer is very complex and requires the expertise of specialists. No party can do this by itself. I believe this result is a fine example of how you can maximize the innovative power of small and medium-sized businesses by joining forces and connecting with the advanced facilities and high-quality knowledge of institutions such as Radboud university medical center and Radboud University.” 

More information


Pieter Lomans

information officer

(024) 81 87012

Related news items


Terrestrial bacteria can grow on nutrients from space

26 May 2020

Researchers from the Radboudumc describe in an article in Astrobiology that bacteria can survive on an 'extraterrestrial diet', which affected their pathogenic potential.

read more

The new front line: big data podcast

22 May 2020

What role do big data and technology play in the fight against corona? What data can help save lives? How do you ensure that your personal health data is used safely? Among others, Peter-Bram 't Hoen explains.

read more

OARSI Basic Science Award for Peter van der Kraan

22 May 2020

Purpose of this Basic Science Award of the Osteoarthritis Research Society International (OARSI) is to stimulate fundamental research in the field of osteoarthritis.

read more

Evaluation of an AI system for detection of COVID-19 on Chest X-Ray images

22 May 2020

In the journal Radiology RIHS researcher Keelin Murphy described how an artificial intelligence system (CAD4COVID-XRay) can identify characteristics of COVID-19 on chest x-rays with performance comparable to six independent radiologists.

read more

First clinical trial with genetically modified malaria vaccine completed

22 May 2020

In an innovative study, Radboudumc and LUMC jointly tested a candidate vaccine based on a genetically weakened malaria parasite. The results of this clinical trial, published in Science Translational Medicine, show that the vaccine is safe and elicits a defense response against a malaria infection.

read more

New step in the development of a vaccine against malaria

22 May 2020

A new vaccine based on rodent malaria parasites achieved a 95% reduction in infection of the liver in humans. An international consortium publishes the results in Science Translational Medicine.

read more